Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program

DURHAM, N.C. --(BUSINESS WIRE)--Mar. 11, 2026-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it has received two Notices